Table of contents
From the editors
p157 | doi:10.1038/nrc2352
Research Highlights
Tumour suppressors: Where to begin? | PDF (134 KB)
p159 | doi:10.1038/nrc2336
Genetics: A numbers game | PDF (473 KB)
p160 | doi:10.1038/nrc2332
Cancer stem cells: Developmental block | PDF (276 KB)
p160 | doi:10.1038/nrc2335
In the news
An aspirational combination | PDF (78 KB)
p160 | doi:10.1038/nrc2340
In brief
Resistance | Oncogenes | Senescence | PDF (94 KB)
p161 | doi:10.1038/nrc2339
Tumour suppressors: One-hit wonder | PDF (119 KB)
p162 | doi:10.1038/nrc2334
Metabolism: The importance of polarity | PDF (311 KB)
p162 | doi:10.1038/nrc2337
Mouse models: An easier option | PDF (282 KB)
p163 | doi:10.1038/nrc2331
Angiogenesis: Blood born killer? | PDF (201 KB)
p164 | doi:10.1038/nrc2330
Leukaemia: Lessons from an ancestor | PDF (273 KB)
p164 | doi:10.1038/nrc2333
Trial Watch
Long-term protection | PDF (136 KB)
p164 | doi:10.1038/nrc2338
Trial Watch
Rapamycin hits the target | PDF (83 KB)
p165 | doi:10.1038/nrc2341
Reviews
Telomerase and cancer therapeutics
Calvin B. Harley
p167 | doi:10.1038/nrc2275
A specific telomerase inhibitor and several telomerase therapeutic vaccines are in clinical trials, and other telomerase-based therapies are in preclinical development. What are the advantages and disadvantages of these approaches and which cancer patients might benefit most?
Article series: Hypoxia and metabolism
Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability
Robert G. Bristow & Richard P. Hill
p180 | doi:10.1038/nrc2344
Intratumoural hypoxia is a negative prognostic indicator and can underlie therapeutic resistance for many patients. This Review explores the differential biological effects of acute hypoxia versus longer-term, chronic hypoxia on genomic instability and DNA damage repair pathways. What does this mean for therapeutic strategies?
DNA repair pathways as targets for cancer therapy
Thomas Helleday, Eva Petermann, Cecilia Lundin, Ben Hodgson & Ricky A. Sharma
p193 | doi:10.1038/nrc2342
Can we exploit the DNA repair pathways in cancer cells to increase the efficacy of existing and future cancer treatments? This Review discusses the current state of play.
Mechanisms linking physical activity with cancer
Anne McTiernan
p205 | doi:10.1038/nrc2325
Up to one-third of cancers are due to excess weight and insufficient physical activity. What mechanisms are involved and can physical activity interventions reduce cancer risk?
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
Akeila Bellahcène, Vincent Castronovo, Kalu U. E. Ogbureke, Larry W. Fisher & Neal S. Fedarko
p212 | doi:10.1038/nrc2345
The family of glycophosphoproteins known as small integrin-binding ligand N-linked glycoproteins (SIBLINGs) are emerging as important players in malignant transformation, invasion and metastasis. Could these proteins be promising diagnostic and prognostic tools, as well as therapeutic targets?
Perspectives
Opinion
Integrative mathematical oncology
Alexander R. A. Anderson & Vito Quaranta
p227 | doi:10.1038/nrc2329
To achieve a comprehensive mechanistic view of the cancer process do we need to assemble a physically integrated team of interdisciplinary scientists that includes mathematicians? This Perspective discusses the useful insights provided by such an interaction.
Article series: MYC
Opinion
MYC in mammalian epidermis: how can an oncogene stimulate differentiation?
Fiona M. Watt, Michaela Frye & Salvador Aznar Benitah
p234 | doi:10.1038/nrc2328
The discovery that the oncogene MYC can stimulate differentiation rather than proliferation in human epidermal stem cells was, understandably, greeted with scepticism. However, subsequent studies have revealed important concepts that are relevant to the function of MYC in tumorigenesis.
Correspondence
Correspondence: FOXM1: The Achilles' heel of cancer?
Senthil K. Radhakrishnan & Andrei L. Gartel
p242 | doi:10.1038/nrc2223-c1
Corrigendum: Targeting the protein kinase C family: are we there yet?
Helen J. Mackay & Christopher J. Twelves
doi:10.1038/nrc2350
